Wharton 13F Backtest: Portfolio Tracking & Replication Lag

Academic literature has long investigated whether individual investors can systematically outperform the broader market by cloning Warren Buffett’s public equity disclosures. Quantitative backtesting frameworks inside the Berkshire Hathaway 13F portfolio tracker evaluate the true alpha generated by 13F replication strategies.

Studies utilizing Wharton Research Data Services (WRDS) demonstrate that an equal-weighted or market-cap-weighted clone of Berkshire’s top holdings historically generated between 200 and 400 basis points of annual alpha over the S&P 500, even after factoring in the mandatory 45-day filing lag.

However, practical implementation challenges—including transaction slippage during crowded filing release days, trading costs on portfolio rebalancing, and inability to replicate Berkshire’s private preferred equity and unlisted wholly owned subsidiaries—impose significant real-world friction on copycat portfolios.